Author

Nicolle Bonar

Observed name: N. Bonar

Institution: EVERSANA (Canada)

Observed institution: EVERSANA (Canada)

ORCID: 0009-0000-3070-4664

Observed ORCID: 0009-0000-3070-4664

OpenAlex ID: A5111084770

Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

2024 · Shaji Kumar, Katja C Weisel, et al. · Journal of Clinical Oncology · 6

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

2026 · Shaji Kumar, Sundar Jagannath, et al. · Blood Cancer Journal · 4

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

2024 · Shaji Kumar, Sundar Jagannath, et al. · Blood · 3

SA47 Use of an Independent Data Review Committee to Promote Best Practices for External Control Arms: A Case Study in Relapsed/Refractory Multiple Myeloma

2025 · Uwe Siebert, M. Alan Brookhart, et al. · Value in Health · 2

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

2026 · Shaji Kumar, Katja C. Weisel, et al. · Blood Cancer Journal · 1

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis

2025 · Lucio N. Gordan, Rohan Medhekar, et al. · Hematological Oncology · 1

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

2023 · Lucio Gordan, Rohan Medhekar, et al. · Blood · 1

Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.

2026 · Meletios A. Dimopoulos, Jorge Monge Urrea, et al. · Journal of Clinical Oncology

Abstract PS5-04-02: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

2026 · C. Brezden-Masley, S. Shokar, et al. · Clinical Cancer Research

Abstract PS2-06-08: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

2026 · C. Brezden-Masley, S. Shokar, et al. · Clinical Cancer Research

Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol

2025 · Christine Brezden-Masley, Rana Qadeer, et al. · BMJ Open

Concordance between blinded independent central review committee and physician-assessed responses: Analyses based on a real-world external control arm in relapsed/refractory multiple myeloma using International Myeloma Working Group data.

2025 · Brian G. Durie, Laura Rosiñol, et al. · Journal of Clinical Oncology

2. Blown Away: the Impact of the Wolfe Island Wind Turbines on Local Bat Populations

2018 · Victoria Attridge, Nicolle Bonar, et al. · Inquiry Queen s Undergraduate Research Conference Proceedings

Works count: 13

Citation count: 18

H-index: 3

I10-index: